Navigation Links
GenturaDx Announces Formation of Scientific Advisory Board

HAYWARD, Calif., Nov. 22, 2011 /PRNewswire/ -- Molecular diagnostics company GenturaDx announced the creation of its scientific advisory board with the appointment of three initial members: Dr. Keith Jerome, M.D., Ph.D., Dr. Steven Miller, M.D., Ph.D., and Dr. Gregory Tsongalis, Ph.D., H.C.L.D., F.A.C.B. The board will provide expert perspectives across science, laboratory medicine and the commercial market related to initial test development and future applications of the company's proprietary IDbox™. The IDbox system is set to begin clinical trials in 2012.

"We are honored to have attracted these renowned scientists and industry leaders who bring a broad perspective to our work and will lend their expertise enabling GenturaDx to bring its fully integrated platform into the clinical laboratory," said Dr. Tsongalis, Senior Vice President of Research and Development.

Dr. Jerome is a widely published expert on herpes simplex virus (HSV) and viral infections more generally. He currently serves as the Director of the Molecular Virology Laboratory in the Department of Laboratory Medicine, and as Associate Professor in Laboratory Medicine at the University of Washington in Seattle, WA.  Dr. Jerome is an Associate Editor of Diagnostic Microbiology and Infectious Diseases and on the Editorial Advisory Board of the Journal of Infectious Diseases.

Dr. Miller is the Medical Director of the UCSF Clinical Microbiology Laboratory and is Assistant Professor in the Department of Laboratory Medicine at the University of California in San Francisco, CA.  His research focuses on the use of molecular methods for diagnosis and monitoring of infectious disease and the evaluation of clinical utility of new test methods, with resulting changes in patient management and improvements in patient care.

Dr. Tsongalis is a High Complexity Clinical Laboratory Director, a Fellow in the Academy of Clinical Biochemistry and serves as the Director of Molecular Pathology in the Department of Pathology at the Dartmouth-Hitchcock Medical Center in Lebanon, NH. He also serves as Co-Director of the Pathology Translational Research Core Facility and Pharmacogenomics Program, Dartmouth-Hitchcock Medical Center. Tsongalis is on the editorial board of Archives of Pathology and Laboratory Medicine, Journal of Clinical Virology, Journal of Molecular Diagnostics and Clinical Chemistry and Laboratory Medicine. His area of expertise is in clinical molecular diagnostic applications for genetic, hematologic, infectious and neoplastic diseases.

"The ability of GenturaDx to attract industry leaders like Drs. Jerome, Miller and Tsongalis, further validates GenturaDx's innovative technology and continual progress," said GenturaDx's CEO Mark Bagnall. "We are thrilled to call them our advisors."

About GenturaDx

GenturaDx is a molecular diagnostic company focused on making high-performance molecular diagnostics both affordable and practical for any laboratory to perform. The company is developing a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide – circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform incorporates sample preparation with proprietary, real-time PCR amplification and detection, reducing the risk of contamination and saving time. The platform's unique engineering design and intuitive interface relies on semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test. For more information, go to

SOURCE GenturaDx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):